In multiple small studies, the use of #hydroxychloroquine
has been found to cure or significantly reduce symptoms of #Covid19
in almost every patient.
A team of #French
doctors published a paper in the science journal IHU Méditerranée Infection where they describe a small study of 80 patients in which all but one 86-year old patient and another 74-year old patient showed improvement after taking a combination of hydroxychloroquine and #azithromycin
. “For all other patients in the cohort of 80 people, the combination of hydroxychloroquine and azithromycin resulted in a clinical improvement that appeared significant when compared to the natural evolution in patients with a definite outcome.” – Didier Raoult, et al.
Chinese researchers published another study just days later, concluding that hydroxychloroquine was successful in reducing symptoms of Covid-19 in mild to moderately ill patients, including cough, fever, and #pneumonia
. “It’s going to send a ripple of excitement out through the treating community.” – Dr. William Schaffner, Infectious Disease Expert, #VanderbiltUniversity
This trial, unlike the one conducted in #France
, did have a control group and patients were meticulously chosen to exclude those who may have illnesses that could be exasperated by hydroxychloroquine, such as liver or kidney problems. They also did not administer azithromycin.
study of 62 patients found that over four in five of those given the drug had their pneumonia symptoms eased opposed to just over half of those which were given only regular care, including, oxygen, antiviral drugs, and other treatments.
The FDA is still unsure about hydroxychloroquine because of a lack of large studies, but it does currently show promise in treating mild to moderate cases of the virus. “If you want to treat people who are already seriously ill, we don’t know how well this will work,” says Dr. Schaffner, “but it does reinforce… the thinking about the nature of many of these pneumonias we are seeing.” 🖐🏾More in comments👇🏾#Event201 #GlobalHealthSecurityAgenda